VEGF significance in peritoneal recurrence from gastric cancer

Aoyagi, Keishiro; Kouhuji, Kikuo; Yano, Shoichiro; Miyagi, Motoshi; Imaizumi, T; Takeda, Jinryo; Shirouzu, Kazuo

doi:10.1007/s10120-005-0329-4

Cited by 49 publications

(37 citation statements)

References 18 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies on the role of the VEGF family in gastric cancer have focused on individual VEGF members and their respective receptors [14,15,18] . The evaluation of the simultaneous expression of VEGF family members and their receptors may provide more accurate prognostic information [17] .…”

Section: Discussionmentioning

confidence: 99%

“…It has been shown that high serum VEGF levels correlate with poor prognosis in certain hematological malignancies [28,29] . In gastric cancer, it has been shown that serum VEGF-A levels correlated with local tumor extent, disease stage, and the presence of distant metastases, and is an independent prognostic factor for patient survival [14,15,20] . Recently, Wang et al [9] reported that serum VEGF-C levels might be a useful biomarker to determine the presence of lymph node metastasis in patients with gastric cancer as well as correlate with VEGF-C tissue expression [18] .…”

Section: Discussionmentioning

confidence: 99%

“…Among angiogenic stimulators, VEGF-A plays an essential role in both vasculogenesis and angiogenesis [14] . Serum concentrations of VEGF-A have been examined in patients with gastric cancer and a relationship between the serum concentration of VEGF and metastasis and/or poor outcome has been demonstrated [15,16] .…”

Section: Introductionmentioning

confidence: 99%

“…Recently, the prognostic importance of serum concentrations of other VEGF family members (VEGF-C and -D and their receptors) in gastric cancer has been reported [18,19] . Overall, these studies were limited to one or two VEGF family members and their receptors and did not examine the full profile of expression of these proteins in the same patient [14,15,18] .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Al-Moundhri¹,

Al-Shukaili²,

Al-Nabhani³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM:To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. METHODS:The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. RESULTS:The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P < 0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9,

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Al-Moundhri¹,

Al-Shukaili²,

Al-Nabhani³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…Angiogenic factors such as vascular endothelial growth factor (VEGF)-A and VEGF-C secreted from peritoneal free cancer cells induce vascular neogenesis in the peritoneal-blood barrier. (24,25) As a result, the distance of the peritoneal-blood barrier shortens and an environment with a rich vasculature is established. VEGF is a well-known angiogenic factor that induces a mitogenic signal for endothelial cells by binding to endothelial cell receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR).…”

Section: Molecular Mechanisms Of Peritoneal Disseminationmentioning

confidence: 99%

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

et al. 2006

View full text Add to dashboard Cite

Peritoneal dissemination is the most common cause of metastasis from malignancies in the abdominal cavity. There are no standard treatments for peritoneal dissemination and the results are poor. The reasons for this are as follows: (1) no effective chemotherapeutic agents have been identified or developed; (2) surgical cytoreduction has little effect on survival improvement; and (3) the molecular mechanisms of peritoneal dissemination have not been clarified and no therapy against the target molecules has been developed. However, studies on the molecular mechanisms of peritoneal dissemination have elucidated some of the target molecules and the development of new multimodal therapies has also improved survival. Early postoperative intraperitoneal chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and neoadjuvant intraperitoneal-systemic chemotherapy have been newly developed, and a novel surgical therapy named peritonectomy has been proposed to perform complete cytoreduction of peritoneal dissemination. At present, these approaches appear to be effective therapeutic modalities for peritoneal dissemination. However, TS-1 and capecitabine have shown worthwhile results in recent clinical trials for patients with advanced gastric cancer. We recently found that newly developed antitumor cytosine nucleoside analogs show a survival advantage in peritoneal dissemination models using human cancer cells. These non-fluoropyrimidine nucleosides may potentially help to improve the poor prognosis observed in patients with advanced cancers involving peritoneal dissemination. (Cancer Sci 2007; 98: 11-18) P eritoneal dissemination remains the most difficult type of metastasis to treat, and almost all surgeons believe that an operation is not indicated for such metastasis.(1-3) Systemic chemotherapy tends to have little effect on the treatment of peritoneal dissemination, because the peritoneal-blood barrier existing between mesothelial cells and the submesothelial capillary hinders drug distribution throughout the peritoneal cavity. Recent advances in the studies of new drugs and multimodal therapies have proposed the therapeutic potency for advanced cancer with peritoneal dissemination. Neoadjuvant chemotherapy is also known to reduce the tumor burden, thus resulting in a stage reduction. As a result, the incidence of complete cytoreduction may increase after neoadjuvant chemotherapy. A new type of neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) has been developed to increase the rate of complete cytoreduction. The complete removal of peritoneal dissemination is an independent prognostic factor. A peritonectomy is a novel surgical procedure by which complete cytoreduction for peritoneal dissemination is performed.(5-8) These approaches are now being carried out as treatment modalities for peritoneal dissemination from appendiceal, colon and gastric cancer. Furthermore, several recent phase II studies that evaluated the efficacy of new anticancer drugs including taxanes, TS-1 and capecitabine have shown p...

show abstract

Follow-Up After Gastric Cancer Treatment

Kim

2019

Surgery for Gastric Cancer

View full text Add to dashboard Cite

VEGF significance in peritoneal recurrence from gastric cancer

Abstract: VEGF score was a significant parameter of peritoneal recurrence. Conclusion. These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer, and that VEGF was a useful indicator of peritoneal recurrence.

Cited by 49 publications

References 18 publications

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites

Follow-Up After Gastric Cancer Treatment

Contact Info

Product

Resources

About